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Background: Current multicomponent scores that predict mortality in COPD patients
might underestimate the systemic component of COPD. Therefore, we evaluated the
accuracy of circulating levels of proadrenomedullin (MR-proADM) alone or combined
with the ADO (Age, Dyspnoea, airflow Obstruction), updated ADO or BOD (Body mass
index, airflow Obstruction, Dyspnoea) index to predict all-cause mortality in stable COPD
patients.
Methods: This study pooled data of 1285 patients from the COMIC and PROMISE-COPD study.
Results: Patients with high MR-proADM levels (0.87 nmol/l) had a 2.1 fold higher risk of




Adrenomedullin optimises mortality prediction 735(ADO plus MR-proADM) (C Z 0.72) was the most accurate predictor followed by the BODA
(BOD plus MR-proADM) (C Z 0.71) and the updated ADOA index (updated ADO plus MR-
proADM) (C Z 0.70). Adding MR-proADM to ADO and BOD was superior in forecasting 1-
and 2-year mortality. The net percentages of persons with events correctly reclassified
(NRIþ) within respectively 1-year and 2-year was 31% and 20% for ADO, 31% and 20% for up-
dated ADO and 25% and 19% for BOD. The net percentages of persons without events
correctly reclassified (NRI-) within respectively 1-year and 2-year was 26% and 27% for
ADO, 27% and 28% for updated ADO and 34% and 34% for BOD.
Conclusions: Adding MR-proADM increased the predictive power of BOD, ADO and updated
ADO index.
ª 2015 Elsevier Ltd. All rights reserved.Background
COPD is a main cause of morbidity and mortality. The dis-
ease is associated with premature death due to pulmonary
complications or associated comorbidities [1].
The assessment of predictors to determine time-to-
death probability and other clinically relevant outcomes
is a topic of major interest. Although several multicompo-
nent indices are available, larger studies or pooling of data
from multiple studies are required to demonstrate external
generalisability and robustness of the parameters and
indices found.
One well-validated multidimensional tool is the Body
mass index, airflow Obstruction, Dyspnoea, Exercise ca-
pacity (BODE) index, which is based on the body mass
index, FEV1 % predicted, modified Medical Research
Council dyspnoea grade (mMRC), and 6-min-walk distance
(6MWD) [2]. Another multidimensional tool is the ADO
index, which combines Age, Dyspnoea (mMRC) and airflow
Obstruction (FEV1 % predicted). Both the BODE and the
ADO index were recently internationally validated and
updated [3,4].
Although both index scores are multicomponent scores,
the systemic component of COPD may be under reflected
in these scores. The influence of comorbidities in mor-
tality seems to be underestimated by the BODEeindex.
Accordingly, a disease-specific comorbidities index (COTE
index) in addition to BODE has been proposed to improve
its mortality prediction in COPD [5]. Furthermore, the
BODE has a practical limitation, since it requires a 6-min
walking test (6MWT), which makes it more cumbersome
in many clinical settings. The use of the BOD, BODE
without exercise capacity measurement, has therefore
been suggested [6,7].
The predictive quality of current tools might be
increased by the inclusion of systemic biomarkers into the
multidimensional tools. A very promising biomarker is
midrange-proadrenomedulin (MR-proADM). MR-proADM is
the more stable precursor of adrenomedulin (ADM), which
closely reflects the level of active ADM. MR-proADM has
been shown to be an independent predictor of mortality
when measured at hospitalisation for an acute exacerba-
tion of COPD (AECOPD) [8] and in stable state [7,9].Patients presenting with circulating levels of MR-proADM
levels above 0$71 nmol/L had a 3-fold higher risk of dying
[9]. In patients with stable COPD, MR-proADM plus BODE
predicts mortality better than BODE alone. Also, MR-
proADM plus BOD predicts mortality more accurately than
BODE alone [7].
The primary aim of the present analysis was to evaluate
the accuracy of circulating levels of MR-proADM alone or in
combination with ADO, the updated ADO or BOD to predict
all-cause mortality in a pooled assessment of two large
European, prospective observational cohort studies of pa-
tients with COPD in stable state.
Methods
Setting and study population
This analysis is a pooled analysis of individual patient-data
from both the COMIC and PROMISE-COPD study.
The COMIC study is a single centre cohort study from
Enschede, the Netherlands. From December 2005 till April
2010, 795 patients were included with a follow-up period of
minimally three years.
The PROMISE-COPD study consecutively recruited and
followed 638 patients of 11 pulmonology departments of
European hospitals from November 2008eOctober 2011.
Detailed in- and exclusion criteria of both studies are
included in the Online supplement.
Outcomes
The primary outcome parameter was survival, based on all-
cause mortality. Date of death was verified from public
registries.
Spirometry was administered by trained respiratory
technicians according to the American Thoracic Society
guidelines [10]. Data on common co-morbidities like
myocardial infarction, congestive heart failure and dia-
betes mellitus were obtained from medical records and/or
during study visits [11e14]. Patients completed the modi-
fied Medical Research Council dyspnoea questionnaire
(mMRC) in local languages, in validated versions when
Table 1 Baseline characteristics of 1285 individuals with
stable COPD included in this analysis.
COMIC PROMISE-COPD p-value
N Z 671 N Z 614
Mean age in y (SD) 67.3 (9.5) 67.0 (9.5) 0.576
Male (n (%)) 404 (60.2) 432 (70.4) <0.001
Current smoker (n (%)) 170 (25.3) 204 (33.4) 0.002
Mean pack-years (SD)a 37.7 (22.9) 50.8 (29.8) <0.001
Mean BMI (SD)b 27.4 (5.4) 26.0 (5.5) <0.001
Lung functionc
Mean FEV1 in l (SD) 1.5 (0.6) 1.3 (0.5) 0.001
Mean FEV1 %
pred(SD)
53.6 (19.1) 49.4 (16.7) <0.001
GOLD stage (n (%))d <0.001
I 63 (9.4) 16 (2.6)
II 299 (44.6) 280 (45.8)
III 252 (37.6) 214 (35.0)
IV 56 (8.4) 101 (16.5)
Mean mMRC score (SD)e 1.8 (1.3) 1.7 (1.2) 0.776
Mean BOD score (SD)f 2.4 (1.8) 2.6 (1.8) 0.163
Mean ADO score (SD)g 4.1 (1.8) 4.1 (1.7) 0.769
Mean updated ADO
score (SD)g




112 (16.7) 93 (15.2) 0.465
Myocardial infarctioni 27 (4.0) 58 (9.5) <0.001
Diabetes mellitusj 43 (6.4) 74 (12.2) <0.001
Abbreviations; SD: Standard Deviation; BMI: Body Mass Index;
FEV1: Forced Expiratory Volume in 1 s; GOLD: Global Initiative
for Chronic Obstructive Lung disease; mMRC: modified Medical
Research Council Dyspnoea grade; BOD: Index that combines
Body mass, airflow Obstruction (FEV1% predicted), Dyspnoea
(mMRC); ADO: Index that combines Age, Dyspnoea (mMRC) and
airflow Obstruction (FEV1% predicted).
a Pack-years of resp. 626 and 593 patients in the COMIC and
PROMISE-COPD study.
b BMI of resp. 658 and 612 patients.
c Lung function measures of resp. 670 and 564 patients.
d GOLD stage of resp. 670 and 611 patients.
e MMRC score of resp. 654 and 599 patients.
f BOD score of resp. 642 and 552 patients.
g ADO and updated ADO score of resp. 653 and 544 patients.
h Diagnosis of congestive heart failure was recorded of 612
patients in the PROMISE-COPD study.
i Diagnosis of myocardial infarction was recorded of 611 pa-
tients in the PROMISE-COPD study.
j Diagnosis of diabetes mellitus was recorded of 608 patients
in the PROMISE-COPD study.
736 M. Brusse-Keizer et al.available [15]. The BOD comprises BODE without exercise
capacity measurement [6]. The components were scored
according to the same cut-offs as in BODE [2]. The BOD
therefore ranges from 0 to 7 [7]. The original and updated
ADO score ranges, in increasing severity, from respectively
0 to 10 and from 0 to 14 points [3]. The assignment of points
for the BOD, ADO and updated ADO are described in the
Online supplement. All measurements were performed in
stable state.
Measurement of MR-proADM
MR-proADM levels were measured in plasma obtained at
stable state with an automated sandwich immunoassay
using a time-resolved amplified cryptate emission technol-
ogy (TRACE) [16]. Details of the measurement are included
in the Online supplement.
Statistics
Continuous variables are expressed as mean with standard
deviation (SD) or median with interquartile range (IQR);
categorical variables as counts with corresponding
percentages.
We analysed time to death by KaplaneMeier survival
curves.
We used univariate and multivariate Cox proportional
hazard regression models to establish the relationship of
MR-proADM, the ADO, updated ADO and BOD indices, alone
or combined with MR-proADM (i.e. ADOA, updated ADOA
and BODA), with all-cause mortality. Furthermore, the C-
statistic for the univariate models and the net reclassifi-
cation improvement was calculated. All tests were two-
sided and a p-value of 0$05 or lower was considered sta-
tistically significant. Data were analysed using SPSS, version
20 (SPSS Inc. Chicago IL) or R, version 3.0.1. Further




In total, the studies provided data of a total of 1285 pa-
tients in which MR-proADM could be determined. Table 1
compares baseline characteristics of both study
populations.
Median follow-up times of the COMIC and PROMISE-COPD
study were resp. 915 (824e1068) and 725 (421e764) days.
The 1- and 2 year cumulative survival rates were respec-
tively 92$8% and 85$4% for the COMIC study and 94$3% and
89$2% for the PROMISE-COPD study. Overall mortality dur-
ing follow up was 20$3% (N Z 261), of which resp. 205
(30$6%) in the COMIC and 56 (9$1%) in the PROMISE-COPD
study.
Crude mortality risk prediction
The survival curve for the four quartiles of MR-proADM
(Fig. 1), shows that the fourth quartile of MR-proADM(cut-off at 0$87 nmol/L) was associated with increased
mortality (p < 0$001). As compared to the first quartile,
Hazard Ratios (HRs) of resp. the second, third and fourth
quartile were 1$12 (95%CI 0$72e1$74; p Z 0$617), 1$43
(95%CI 0$95e2$15; p Z 0$090) and 3$70 (95%CI
2$56e5$36; p < 0$001). When MR-proADM level was
dichotomised into low (1st-3rd Quartile) and high (4th
Quartile) mortality risk, the HR of the high risk compared
to the low risk category was 3$1 (95%CI 2$4e4$0;
p < 0$001).
Figure 1 KaplaneMeier survival curve for the four quartiles
of MR-proADM.
Figure 3 KaplaneMeier Survival Curve for the “Updated
ADOA” categories.
Adrenomedullin optimises mortality prediction 737Fig. 2 depicts the survival curve of the four categories of
the ADOA index, which combines low (<6) and high (6)
mortality risk based on the ADO index with low (1st-3rd
Quartile) and high (4th Quartile) mortality risk based on MR-
proADM levels. Each increase in ADOA index category was
associated with increased mortality (p < 0$005). As
compared to the low/low risk category, HRs were 2$8 (95%
CI 1$9e4$0) 4$8 (95%CI 3$4e6$8) and 8$7 (95%CI 6$3e12.0)
(all p < 0$001).Figure 2 KaplaneMeier Survival Curve for the “ADOA”
categories.Fig. 3 presents four categories of the updated ADOA
index, which combines low (<10) and high (10) mortality
risk based on the updated ADO index with low (1ste3rd
Quartile) and high (4th Quartile) mortality risk based on MR-
proADM levels. Also with the updated ADOA index each in-
crease in category was associated with increased mortality
(p < 0$021). As compared to the low/low risk category, HRs
were 2$6 (95%CI 1$8e3$7) 4$2 (95%CI 2$9e5$9) and 7$9 (95%
CI 5$7e10$9) (all p < 0$001).The survival curve of the four categories of the BODA
index (Fig. 4) shows that patients with either high mortality
risk based on MR-proADM or high mortality risk based on theFigure 4 KaplaneMeier Survival Curve for the “BODA”
categories.
Table 2 Univariate Cox-regression models for all-cause mortality prediction.
N Z 1189 HR 95%CI p-value C-statistic
ADO <0.001 0.67
<6 931 1.0
6 258 4.9 3.8e6.3
Updated ADO <0.001 0.65
<10 940 1.0
10 249 4.5 3.5e5.8
MR-proADM <0.001 0.64
Quartile 1e3 896 1.0
Quartile 4 293 3.1 2.4e4.0
BOD <0.001 0.63
<4 855 1.0
4 334 3.2 2.5e4.1
ADOA <0.001 0.72
ADO <6 & MR-proADM <0.87 nmol/l 757 1.0
ADO <6 & MR-proADM 0.87 nmol/l 174 2.8 1.9e4.0
ADO 6 & MR-proADM <0.87 nmol/l 139 4.8 3.4e6.8
ADO  6 & MR-proADM 0.87 nmol/l 119 8.7 6.3e12.0
Updated ADOA <0.001 0.70
ADO <10 & MR-proADM <0.87 nmol/l 763 1.0
ADO <10 & MR-proADM 0.87 nmol/l 177 2.6 1.8e3.7
ADO 10 & MR-proADM <0.87 nmol/l 133 4.2 2.9e5.9
ADO 10 & MR-proADM 0.87 nmol/l 116 7.9 5.7e10.9
BODA <0.001 0.71
BOD <4 & MR-proADM <0.87 nmol/l 663 1.0
BOD <4 & MR-proADM 0.87 nmol/l 192 3.9 2.7e5.5
BOD 4 & MR-proADM <0.87 nmol/l 233 3.9 2.8e5.4
BOD 4 & MR-proADM 0.87 nmol/l 101 8.4 5.8e12.1
Abbreviations; ADO: Index that combines Age, Dyspnoea (mMRC) and airflow Obstruction (FEV1% predicted); Updated ADO: Updated ADO
index as suggested by Puhan et al.; MR-proADM: midrange-proadrenomedulin; BOD: Index that combines Body mass, airflow Obstruction
(FEV1% predicted), Dyspnoea (mMRC); ADOA: Index that combines the ADO index with MR-proADM; Updated ADOA: Index that combines
the updated ADO index with MR-proADM; BODA: Index that combines the BOD index with MR-proADM.
Table 3 Net reclassification of survivors and non-
survivors.
NRIþ NRI-
1-year 2-year 1-year 2-year
ADOA 31 (8e52) 20 (4e35) 26 (20e32) 27 (21e33)
Updated
ADOA
31 (9e53) 20 (4e37) 27 (21e32) 28 (22e34)
BODA 25 (3e47) 19 (3e36) 34 (28e39) 34 (29e40)
Abbreviations; ADOA: Index that combines the ADO index with
MR-proADM; Updated ADOA: Index that combines the updated
ADO index with MR-proADM; BODA: Index that combines the
BOD index with MR-proADM; NRIþ the net percentages of per-
sons with events correctly reclassified; NRI: the net percent-
ages of persons without events correctly reclassified.
738 M. Brusse-Keizer et al.BOD index (4) had an almost equal increased risk of
mortality (p Z 0$97) compared to the low/low risk cate-
gory, with HRs of resp. 3$9 (95%CI 2$7e5$5; p < 0$001) and
3$9 (95%CI 2$8e5$4; p < 0$001). High mortality risk based
on both the BOD index and MR-proADM was associated with
a further increase in mortality (HR 8$4; 95%CI 5$8e12$1;
p < 0$001).
Table 2 presents the univariate Cox regression analyses of
all indices. Based on the C-statistics of the separate indices
and MR-proADM the ADO index was the most accurate pre-
dictor (highest C-statistic). Adding MR-proADM to the BOD
and both the original and updated ADO improved the pre-
dictive power of all three indices. The ADO index was the
most accurate predictor followed by the BODA index.
Adding MR-proADM to ADO and BOD showed superior
ability to forecast 1-year and 2-year survival and non-
survival (see Table 3). The net percentages of persons with
events correctly reclassified (NRIþ) when adding MR-
proADM to the indices within respectively 1-year and 2-year
is 31% and 20% for ADO, 31% and 20% for updated ADO and
25% and 19% for BOD.
The net percentages of persons without events correctly
reclassified (NRI) when adding MR-proADM to the indices
within respectively 1-year and 2-year is 26% and 27% for
ADO, 27% and 28% for updated ADO and 34% and 34% for
BOD.Multivariable adjusted mortality risk prediction
Table 4 depicts multivariate Cox-regression analyses. After
adjustment for confounders, the HR for mortality remained
significantly higher in patients with high compared to low
mortality risk based on MR-proADM levels (HR 2$1 (95%CI
1$6e2$8; p < 0$001).
Table 4 Multivariate Cox-regression models for all-cause mortality prediction.
N Z 1185 HR 95%CI p-value
ADOa <0.001
<6 929 1.0
6 256 4.3 3.4e5.6
Updated ADOa <0.001
<10 938 1.0
10 247 3.9 3.0e5.0
MR-proADMb <0.001
Quartile 1e3 893 1.0
Quartile 4 292 2.1 1.6e2.8
BODc <0.001
<4 853 1.0
4 332 3.0 2.4e3.9
ADOAd <0.001
ADO <6 & MR-proADM <0.87 nmol/l 756 1.0
ADO <6 & MR-proADM 0.87 nmol/l 173 3.3 2.3e4.8
ADO 6 & MR-proADM <0.87 nmol/l 137 4.3 3.1e6.1
ADO 6 & MR-proADM 0.87 nmol/l 119 8.8 6.3e12.2
Updated ADOAd <0.001
ADO <10 & MR-proADM <0.87 nmol/l 762 1.0
ADO <10 & MR-proADM 0.87 nmol/l 176 3.1 2.2e4.5
ADO 10 & MR-proADM <0.87 nmol/l 131 3.4 2.5e5.1
ADO 10 & MR-proADM 0.87 nmol/l 116 7.6 5.5e10.5
BODAc <0.001
BOD <4 & MR-proADM <0.87 nmol/l 662 1.0
BOD <4 & MR-proADM 0.87 nmol/l 191 2.7 1.8e3.9
BOD 4 & MR-proADM <0.87 nmol/l 231 3.8 2.7e5.3
BOD 4 & MR-proADM 0.87 nmol/l 101 5.8 3.9e8.4
Abbreviations; ADO: Index that combines Age, Dyspnoea (mMRC) and airflow Obstruction (FEV1% predicted); Updated ADO: Updated
ADOindex as suggested by Puhan et al.; MR-proADM: midrange-proadrenomedulin; BOD: Index that combines Body mass, airflow
Obstruction (FEV1% predicted), Dyspnoea (mMRC); ADOA: Index that combines the ADO index with MR-proADM; Updated ADOA: Index
that combines the updated ADO index with MR-proADM; BODA: Index that combines the BOD index with MR-proADM; BMI: Body Mass
Index; mMRC: modified Medical Research Council Dyspnoea grade; FEV1: Forced Expiratory Volume in 1 s.
a Corrected for BMI and congestive heart failure.
b Corrected for Age, BMI, mMRC and FEV1 in liters.
c Corrected for Age.
d Corrected for BMI.
Adrenomedullin optimises mortality prediction 739The HRs for the ADOA index risk categories remained
almost unaffected after adjustment (3$3 (95% CI 2$3e4$8),
4$3 (95% CI 3$1e6$1) and 8$8 (95% CI 6$3e12$2) all
p < 0$001). Conversely, in the categories in which there
was either high mortality risk based on MR-proADM (high
MR-proADM/low ADO) or high mortality risk based on the
ADO index (low MR-proADM/high ADO), the risk of survival
was not significantly different (p Z 0$180).
Similarly, with the updated ADOA index there was no
significant difference in survival between patients with high
MR-proADM/low updated ADO risk and with low MR-
proADM/high updated ADO risk (p Z 0.519), with HRs of
resp. 3.1 (95%CI 2.2e4.5) and 3.4 (95% CI 2.5e5.1).
The univariate BODA index analysis already showed that
patients with either high mortality risk based on MR-proADM
(high MR-proADM/low BOD) or high mortality risk based on
the BOD index (low MR-proADM/high BOD) had an almost
equal increased risk of mortality compared to the low/low
risk category. Although this finding remained unchanged
(p Z 0$059), the risk of mortality seemed somewhat higher
in the low MR-proADM/high BOD risk category (HR Z 3$8;95%CI 2$7e5$3) as compared to the high MR-proADM/low
BOD risk category (HR Z 2$7; 95%CI 1$8e3$9). High mor-
tality risk based on both the BOD index and MR-proADM
(high/high) showed a decreased risk (HR 5$8; 95%CI
3$9e8$4) of mortality after adjustment for confounders.Discussion
In this pooled assessment of two large European prospec-
tive observational cohort studies of patients with COPD, we
could examine, for the first time, whether adding MR-
proADM to the BOD, ADO and updated ADO indices increases
the predictive probability of all three indices. We could
demonstrate that patients with high MR-proADM levels had
a significant increased risk of dying. Additionally, the
combination of MR-proADM with ADO, updated ADO and
BOD improved significantly the predictive power of the
clinical indices.
The additive predictive value of MR-proADM to both the
original updated ADO and BOD index supports the
740 M. Brusse-Keizer et al.underestimation of the systemic component in COPD in all
three indices. The COTE index already showed that adding
a comorbidity score to the BODE index increased its prog-
nostic properties. However, the COTE index needs system-
atical recording of comorbidities, since it scores the
presence of twelve comorbidities [5]. This makes it harder
to apply in most clinical settings than the measurement of
an MR-proADM level in stable COPD patients.
Compared to the predictive value of the BODE index, the
BODA index, which includes the BOD index and MR-proADM,
had a slightly lower predictive value based on the C-statistic
(respectively C Z 0$74 and 0$71) [2]. Although the predic-
tive power is slightly lower, MR-proADM measurement rep-
resents a good alternative to the 6MWD for mortality
prediction. [7] Replacing the 6MWD by MR-proADM could
potentially improve the feasibility of the BODE index, since
difficulties in performing the 6MWT have been previously
described (i.e., requirement of a long, flat, straight,
enclosed corridor with a hard surface that is seldom trav-
elled and must be 30 m in length; trained personnel; access
to rapid, appropriate response to an emergency) [7]. The
challenges associated with assessing the 6MWD lead to the
development of indices refraining from measurement of the
walking distances, such as the ADO index, a more simplified
index that includes solely age, dyspnoea and airflow
obstruction [4]. Based on the C-statistic, both the ADO and
the updated ADO index had a numerically higher predictive
value than the BOD index. Adding MR-proADM to both the
original and the updated ADO index led to a comparable
increased predictive probability as seen when adding MR-
proADM to the BOD index (resp. C Z 0$72, 0$70, and
0$71), suggesting that all three can be used without pref-
erence in every day clinical practice. And also the 1-year and
2-year mortality net correct reclassification of survivors and
non-survivors when MR-proADM was added to the indices was
comparable for all three indices. Next to this, the HR’s of all
separate and combined indices were similar when the ana-
lyses were stratified according to disease stage (GOLD stage I
and II versus stage III and IV) (see Online supplement), sug-
gesting that the risk for mortality in both mild to moderate
and severe COPD patients is equally increased when patients
are above the cut-off values of the indices.
The cut-off of MR-proADM in this pooled assessment
(0$87 nmol/L) was higher than the cut-offs previously
described (0$71 nmol/L) [9] (0$75 nmol/L) [7]. On the one
hand this might be due to the fact that the current, opti-
mised cut-off represents the fourth quartile instead of the
median. (Fig. 1). On the other hand, the difference in
optimal cut-off could be additionally explained by the di-
versity of populations that were studied. The cut-off sug-
gested by Zuur-Telgen et al. derived from a small subset of
patients in the COMIC study that provided a paired plasma
sample, both in stable state and at hospitalisation for an
AECOPD. Due to this selection, patients deceasing during
the hospitalisation or before reaching clinical stability were
excluded from the analysis.
Our study has a few limitations. The main one is that we
have not systematically recorded all co-morbidities in the
COMIC study. Only common co-morbidities such as
myocardial infarction, congestive heart failure and dia-
betes mellitus were noted, since these were probably
related to MR-proADM due to its vascular activity andrelated to survival. Therefore, we were not able to calcu-
late the COTE index in this pooled assessment and to
analyse the additive effect of MR-proADM to this index.
Accordingly, we were not able to correct for other poten-
tially confounding co-morbidities in the multivariate Cox
proportional hazard analyses.
Although prednisolone has shown to inhibit MR-proADM
levels [17], we do not expect systemic steroids to alter
circulating proADM levels in the current study, since all pa-
tients were stable for at least 4 weeks before being included
in this cohort study. This far, we are not aware whether the
use of inhaled corticosteroids can also influence MR-proADM
levels. We however do know that approximately eighty
percent of the studiedpatients usean inhaled corticosteroid.
Furthermore, we are not able to compare the BOD and BODA
with the BODE score in this pooled assessment since we did
not perform a 6MWT in the COMIC study. Previous data sug-
gest that the performance of the BODE index is significantly
improved by the addition of MR-proADM [7]. Next to this, we
observed a difference in mortality between the COMIC and
PROMISE-COPD study (respectively 30$6and9$1%). Apossible
explanationmight be that a considerable number of patients
of the COMIC study were hospitalised for an AECOPD before
the stable state level of MR-proADM and the other indices
were measured. These patients having might have a worse
prognosis. Additionally, the difference in follow-up (915 and
725 days, respectively) may have contributed to the differ-
ence in mortality. Furthermore, differences in the presence
of other co-morbidities than the ones we studied may have
contributed as well.
Finally, current results are pertinent to well-treated and
characterised patients and might not reflect those observed
in less severe, slightly undertreated patients.
Although MR-proADM has shown to contribute to prog-
nostication, the perhaps most important question remains:
How can prognostication improve patient care in COPD?
Prognostication could be valuable if it could guide adjust-
ment of care (more frequent contacts, additional medica-
tion, rehabilitation, and so forth) in high risk patients to
eventually prolong survival. If, on the other hand, one hy-
pothesizes that high MR-proADM levels combined with one
of the indices predict inevitable death in the near future,
this could perhaps aid in implementing end-of-life (pallia-
tive) care, because this is frequently instituted very late or
not at all in many patients with COPD. Accordingly, whether
optimisation of care or implementing end-of-life (pallia-
tive) care, based on risk stratification, could improve pa-
tient outcomes, should be evaluated in further randomized,
controlled trials.
Furthermore, since most COPD treatments are not pre-
scribed to modify mortality risk, but to reduce exacerba-
tions, and improve symptoms and quality of life, it would
be very interesting to also evaluate the predictive value of
MR-proADM in combination with ADO and BOD for these
important outcomes.Conclusions
In conclusion, adding MR-proADM to the BOD, ADO and
updated ADO index increased the predictive power of all
Adrenomedullin optimises mortality prediction 741three indices. MR-proADM is therefore a potentially valu-
able biomarker in stable COPD.
Take home message
MR-proADM contributes to prognostication by multidimen-
sional scores in stable COPD.
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ADO age, Dyspnoea and airflow Obstruction
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BODA body mass index, airflow Obstruction, Dyspnoea
and proadrenomedullin
BODE body mass index, airflow Obstruction, Dyspnoea
and Exercise capacity
CI confidence interval
COPD chronic obstructive pulmonary disease
COTE COPD specific comorbidity test
HR hazard ratio
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FEV1 forced expiratory volume in 1 s
GOLD global initiative for chronic obstructive lung
disease




NRI Net reclassification Improvement
SD standard deviation
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